key: cord-0821605-rubjalcv
authors: Sahajpal, Nikhil Shri; Jill Lai, Chi-Yu; Hastie, Alex; Mondal, Ashis K.; Dehkordi, Siavash Raeisi; van der Made, Caspar I.; Fedrigo, Olivier; Al-Ajli, Farooq; Jalnapurkar, Sawan; Byrska-Bishop, Marta; Kanagal-Shamanna, Rashmi; Levy, Brynn; Schieck, Maximilian; Illig, Thomas; Bacanu, Silviu-Alin; Chou, Janet S.; Randolph, Adrienne G.; Rojiani, Amyn M.; Zody, Michael C.; Brownstein, Catherine A.; Beggs, Alan H.; Bafna, Vineet; Jarvis, Erich D.; Hoischen, Alexander; Chaubey, Alka; Kolhe, Ravindra
title: Optical genome mapping identifies rare structural variations as predisposition factors associated with severe COVID-19.
date: 2022-01-10
journal: iScience
DOI: 10.1016/j.isci.2022.103760
sha: 2210e22fefd58114e954650cf030d851968d7677
doc_id: 821605
cord_uid: rubjalcv

Impressive global efforts have identified both rare and common gene variants associated with severe COVID-19 using sequencing technologies. However, these studies lack the sensitivity to accurately detect several classes of variants, especially large structural variants (SVs), which account for a substantial proportion of genetic diversity including clinically relevant variation. We performed optical genome mapping on 52 severely-ill COVID-19 patients to identify rare/unique SVs as decisive predisposition factors associated with COVID-19. We identified 7 SVs involving genes implicated in two key host-viral interaction pathways: innate immunity and inflammatory response, and viral replication and spread in 9 patients, of which SVs in STK26 and DPP4 genes are the most intriguing candidates. This study is the first to systematically assess the potential role of SVs in the pathogenesis of COVID-19 severity and highlights the need to evaluate SVs along with sequencing variants to comprehensively associate genomic information with inter-individual variability in COVID-19 phenotypes.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first reported in the city of 60

Wuhan, China in December 2019 has led to an ongoing global pandemic of coronavirus disease, 61 COVID-19. Since then, there have been almost 241 million COVID-19 cases reported worldwide 62 and over four million COVID-19-related deaths (https://coronavirus.jhu.edu/map.html, last 63

accessed October 20, 2021). The clinical manifestations of SARS-CoV-2 infected patients vary 64 from asymptomatic or mild symptoms, including low-grade fever and flu-like symptoms, to 65 COVID-19 pneumonia and life-threatening acute respiratory distress syndrome (ARDS) (Berlin et 66 al., 2020; Zhu et al., 2020; Zhou et al., 2020a; Williamson et al., 2020; Wu and 67 McGoogan, 2020) . Clinical studies have identified advanced age, male gender, hypertension, 68 diabetes, diseases related to metabolic syndrome, and other chronic diseases, as risk factors 69 associated with COVID-19-related severe illness (Zhou et al., 2020b; Docherty et 70 al. 2020 ). However, variable clinical manifestations within these subsets and poor clinical 71 outcomes in individuals without associated comorbidities or risk factors clearly implicate the role 72 of host genetics in the predisposition of SARS-CoV-2 infected individuals to severe COVID-19 73 (Richardson et al., 2020; Abbasi, 2020) . A recent meta-analysis of host genetic factors in 74 coronaviruses infection identified 1,832 relevant research publications with 105 of high 75 significance. Of the 105 articles, seventy-five investigated human host genetic factors, identifying 76 multiple significant loci, including 16 related to susceptibility (seven of which identified protective 77 alleles) and 16 related to outcomes (three of which identified protective alleles). In addition, 30 78 articles investigated inter-species differences in disease susceptibility and pathogenesis by 79 studying both human and non-human host genetic factors (LoPresti et al., 2020) . 80

To date, two distinct genomic approaches have been used to identify likely disease 81 susceptibility and severity gene variants in COVID-19 patients. The first approach utilizes 82 relatively unbiased genome-wide association studies (GWAS) to understand risk factors at the 83 population level, which provides insights into the pathophysiological mechanisms and biology, 84 but this approach cannot be used to investigate individual patients. The second approach involves 85 short-read gene panel, whole exome, or genome sequencing to identify rare variants in known 86 genes whose biological functions suggest plausible models by which they may function as severe 87

risk factors, such as those that contribute to inborn errors of immunity (IEIs) which remain 88 unremarkable until infection, or completely novel IEIs/ primary immunodeficiencies (PIDs) that 89 predispose to severe COVID-19. Using a GWAS approach, several groups have found blood group 90

A of the ABO groups to be an independent risk factor for COVID-19 related disease susceptibility 91 (Zhao et al., 2020c; Zhao et al., 2020d) . In additional studies, chr3p21.31, chr12q24.13, 92 chr19p13.2, chr19p13.3, and chr21q22.1 loci were associated with severe COVID-19, and blood 93 group A was confirmed to be the risk factor for disease severity (Ellinghaus et al., 2020; Pairo-94 Castineira et al., 2020) . Reports utilizing a targeted variant approach demonstrated the importance 95 of rare/unique events that cause immunodeficiencies and predispose them to severe For example, putative loss of function variants in TLR7 in two different pairs of young and 97 otherwise healthy brothers was associated with severe COVID-19 ( Van der Made et al., 2020) , 98 J o u r n a l P r e -p r o o f this finding was recently replicated . Further, the rare variants in 13 genes in 99 the TLR3 and IRF7 pathway have been implicated as risk factors in patients with severe COVID-100

19 Hadjadj et al., 2020) , although a recent study reported inconsistent findings 101 (Kosmicki et al., 2021) . 102

In a continued effort to understand the varied host response, the COVID-19 Host Genetics 103

Initiative has been established to encourage data generation, sharing, and meta-analysis of the 104 GWAS statistics from around the world (COVID-19 Host Genetics Initiative, 2020) . Although 105 these studies have identified certain genetic loci associated with disease severity, they remain 106 limited to short or single nucleotide variants, which explains only a small portion of the heritability 107 of complex traits. Importantly, structural variants (SVs) that comprise a substantial proportion of 108 genomic variation among individuals, and which can drive evolutionary processes are beyond the 109 purview of these studies as a result of the need for new technologies for sensitive detection of SVs 110 (Eichler, 2019a; Levy-Sakin et al., 2019) . SVs are defined as genetic variants involving larger 111 regions of an individual genome (>50bp) (Eichler et al., 2019b) , and are a diverse group of genetic 112 variants that include copy-number changes, insertions, deletions, inversions, repeat contraction, 113

repeat expansions, and translocations. As these remain difficult to detect by routine short-read 114

next-generation sequencing (Mahmoud et al., 2019) , these categories of SVs have not been 115

investigated with respect to their relationship with COVID-19 predisposition. According to the 116 Human Gene Mutation Database (HGMD), more than 34% of all known disease-causing variations 117 are larger than a single base-pair change, i.e. single nucleotide variation (SNVs) -a trend that has 118 been slowly edging upward over the past decade (Eichler et al., 2019b) . Several studies have 119 demonstrated the importance of large SVs in the characterization of human immunity profiles 120 (Watson ET AL., 2013; Isa et al., 2020) . Despite the host genome investigation initiatives across 121 the globe to understand the genetic predisposition to disease severity in COVID-19, a substantial 122 portion of the genome and variant classes remains intractable because of the technical limitations 123 of applied genomic sequencing technologies (Monlong et al., 2018 ; Brandt et al., 2015) . The 124 major limitation for SV detection using short-read next-generation sequencing is inherent to the 125 data type and alignment algorithms that are effective for unique sequences but break down within 126

repetitive regions, which are highly enriched with SVs (Chaisson et al., 2019) . 127

To address the limited SV analysis related to were intubated prior to admission (PTA), and 13.4% (7/52) were ventilated in prone-position. Of 154 the 52 patients, 39 recovered and 13 died during ICU stay. 155

An unbiased whole-genome mapping investigation of the severely ill patients was performed using 157 a filter for SVs that did not appear in the Bionano controls (Figure 1) . The complete list of 158 rare/unique SVs is provided in Supplementary file 2. On average, each of the 52 individuals with 159

severe COVID-19 carried 40 rare SVs, i.e. a total sum of 2062 rare SVs in 52 cases. This number 160

is very similar to recent manuscripts (using similar controls to define the rare nature of events) 161 . SVs changing the copy number or disrupting the gene coding regions, and 162

implicated in viral host response pathways led to the identification of seven rare/unique SVs, 163

impacting 31 genes, identified in 9 patients that shared common chronic pre-existing conditions. 164

These included genes implicated in innate immunity and inflammatory response (EDARADD, 165 DPP4, ZDHHC1, STK26, CD300 gene cluster), and viral replication and spread (KRT15, KRT19, 166 ZNF443) ( Software. (Table 2) . 171

We next evaluated the impact of a rare X-chromosomal SV that partially duplicates the 5'UTR 173

and coding exon 1 of the STK26 gene (Figure 8) . STK26 (also known as MST4) is widely 174 expressed, with robust expression in monocytes as well as T, B, and NK cells, and has previously 175 been investigated in the context of bacterial, although not viral, infections. It inhibits Toll-like 176 receptor (TLR) signaling by phosphorylating the adaptor protein TRAF6, thereby impairing the 177 assembly of TRAF6-mediated complexes needed for downstream TLR signaling (Jiao et al., 178 2015) . Gene transcripts of STK26 were quantified from the blood of 15 asymptomatic and 13 179 severely ill patients with COVID-19, normalized against 18S rRNA. STK26 transcripts were found 180 to be significantly (7.2 ± 2.3 vs. 1.1 ± 0.5; p<0.001) increased in severely ill patients compared to 181 asymptomatic controls, with the highest expression observed in patient-44 (11.7 fold), who was 182 the patient that harbored the SV partially duplicating the 5'UTR and coding exon 1 of the STK26. 183

Interestingly, the disease-associated elevation of STK26 expression was higher in females (9.0 ± 184 2.6 vs. 1.1 ± 0.4; p<0.001) compared to males (4.8 ± 1.3 vs. 1.2 ± 0.6; p<0.001) when severely ill 185

patients were compared to asymptomatic controls. Gene transcripts for TRAF6 (29.7 ± 11.8 vs. 186

1.6 ± 1.8; p< 0.001) and IRF3 (2.8 ± 1.2 vs. 1.3 ± 0.9; p<0.001) were significantly increased, 187

whereas, the gene transcripts of interferon-stimulated genes, ISG15 (0.9 ± 1.5 vs. 2.7 ± 4.1; p<0.05) 188

and IFIT1 (0.5 ± 0.7 vs. 1.7 ± 2.0; p<0.001) were significantly decreased in severely ill patients 189 compared to asymptomatic controls. Expression of ISG15 and IFIT1 in patient-44 were amongst 190 the lowest in the cohort (Figure 9a-g) . 191

The ~24.1 kb heterozygous deletion on chr2 identified in patient 38 is an intragenic copy number 193 loss of the DPP4 gene deleting exons 3-5. This multi-exonic heterozygous copy number loss 194 results most likely in an out-of-frame deletion (p.Thr32Thrfs*11). DPP4 encodes dipeptidyl 195 peptidase 4 (DPP4), a ubiquitously expressed enzyme that cleaves N-terminal proline-or alanine-196 containing dipeptides. DPP4 exists in two forms: 1) a membrane-bound form and 2) a cleaved 197 product of the receptor (sDPP4) lacking the intracellular and transmembrane domain present in the 198 circulation (Trzaskalski et al., 2020) . sDPP4 interacts with GLP-1 and cytokines and regulates the 199 T-cell receptor-mediated T-cell activation. The sDPP4 serum concentration was significantly 200 decreased in severely ill patients compared to asymptomatic controls (1732.4 ± 1049.6 vs. 3015.3 201 ± 853.0; p<0.05) ng/ml, with the lowest concentration observed in patient 38 (117 ng/ml) ( Figure  202 9h), who harbored the SV of the DPP4 gene (Figure 3) . 203

This study addressed the current technology bias of short-read sequencing that has confined most 205

host genome studies to the interrogation of only SNVs and small indels associated with COVID-206 19 severity (Zhao et al., 2020c; Zhao et al., 2020d; Ellinghaus et al., 2020; Pairo-Castineira et al., 207 2020; Van der Made et al., 2020; Fallerini et al., 2021; Zhang et al., 2020) . A comparison of 208 traditional cytogenetic technologies, short-read sequencing with OGM is provided as 209 supplementary file 5. Although these approaches have been successful in associating certain 210 genetic loci, large gaps remain in explaining the wide diversity of clinical responses. Our data 211

show that large SVs identified using optical genome mapping might further explain the inter-212

individual clinical variability in response to COVID-19. Among 52 patients with severe COVID-213 19, we identified seven rare/unique SVs (not found in 267 Bionano controls) impacting 31 genes. 214

While individual effects of any of these SVs remain difficult to predict, several of these may be 215 considered candidate loci as strongly predisposing factors associated with severe These SVs were implicated in three key host-viral interaction pathways: 1) innate immunity and 217 inflammatory response (EDARADD, DPP4, ZDHHC1, STK26, CD300 gene cluster); and 2) viral 218 replication and spread (KRT15, KRT19, ZNF443,) (Figure 10) . 219

In this investigation, five rare/unique SVs impacting key immune genes (STK26, ZDHHC1, DPP4, 221 EDARADD, and CD300 genes cluster) were identified in six patients. Variability in the host's 222 innate and adaptive immune responses to viral infections clearly can influence clinical 223 manifestations and outcomes (Brubaker et al., 2015; Channappanavar et al., 2019) . The innate 224

immune response is the first line of defense against the invading pathogen and utilizes multiple 225 pattern recognition receptors of which, Toll-like receptors (TLRs) have been implicated as key 226

receptors in the recognition of ssRNA of MERS-CoV and SARS-CoV in murine models 227 (Channappanavar et al., 2019; Choudhuryet al., 2020 predisposing to severe COVID-19. Interestingly, the TRAF6 and IRF3 genes were significantly 246 overexpressed in severely ill patients compared to asymptomatic controls, which is consistent with 247 published reports (Figure 9d,e) , (Sohn et al., 2020) whereas, the interferon-stimulated genes 248 (ISGs), ISG15, and IFIT1 were both significantly downregulated in severely ill patients compared 249

to asymptomatic controls, with the expression of ISGs in case-44 (harboring the STK26 SV) 250

amongst the lowest in the cohort (Figure 4f,g) . The ZDHHC1 gene deleted in a ~146.8 kb heterozygous region in one patient (case 39), is 262 also a gene implicated in the type I interferon response. ZDHHC1 expression has been shown to 263 mount a type I interferon response against DNA and RNA viruses via different downstream players 264 (Xu et al., 2017) . ZDHHC1 encodes an endoplasmic reticulum-associated palmitoyltransferase 265 that mediates MITA-dependent IRF3 activation and type I interferon response against DNA 266 viruses (Figure 10 ) against the Japanese encephalitis virus . Additionally, IFITM3 expression was 273

found to be upregulated early in epithelial lung cells in response to SARS-CoV-2, (Bozzo et al., 274 2020) and that SNPs in IFITM3 are associated with more severe disease (Nikoloudis et al., 2020) . 275 We hypothesize that the heterozygous deletion of the ZDHHC1 gene could compromise the type 276 I interferon response, especially at the level of IFITM3, which might have led to the severe 277 COVID-19 symptoms in this patient. 278

The rare/unique SV involving the DPP4 gene that encodes for T-cell activation antigen 279 CD26 in a severely ill patient (case 38) is consistent with prior studies implicating dipeptidyl 280 peptidase 4 (DPP4) activity in MERS-CoV (Reinhold and Brocke, 2014; Inn et al., 2018) and 281

severe COVID-19 (Schlicht et al., 2020) . Recently, DPP9, a family member of this gene has been 282 associated with severe COVID-19 in a GWAS study (Pairo-Castineira et al., 2021) . Although 283 bioinformatics models predicted human DPP4-SARS-CoV-2 protein interactions, and protein 284 docking studies show SARS-CoV-2 virus utilizes DPP4 as a co-receptor (not as strong as with 285 ACE-2) , in vitro studies found that DPP4 serves as a viral entry receptor for 286 MERS-CoV, but not for SARS-CoV-2 (Letko et al., 2020) . Apart from the membrane-bound 287 receptor, the circulating sDPP4 enzyme interacts with GLP-1 and cytokines and regulates T-cell 288 receptor-mediated T-cell activation. The ~24.1 kb heterozygous deletion on chr2 identified in 289 patient 38 is an intragenic copy number loss of the DPP4 gene deleting exons 3-5. This multi-290 exonic heterozygous copy number loss results most likely in an out-of-frame deletion 291 (p.Thr32Thrfs*11) (Klemann et al., 2016) . Notably, the lowest circulating sDPP4 level was 292 observed in this patient, but in addition, sDDP4 levels were significantly decreased in severely ill 293 patients compared to asymptomatic controls. Circulating sDPP4 levels have been reported to be 294 reduced in both MERS-CoV and SARS-CoV-2 infection but to contrasting effects (Inn et al., 2018; 295 J o u r n a l P r e -p r o o f Schlicht et al., 2020) . In MERS-CoV infection, the sDPP4 levels were below the threshold needed 296

to exert an antiviral effect, as sufficient viral particles were available for entry via the membrane-297 bound receptor. The reduced sDPP4 levels possibly reflect a compromised immune response and 298 may not signify competition for SARS-CoV-2 entry via the DPP4 receptor. Several case reports 299 and the Japanese Adverse Drug Event Report (JADER) have highlighted the risk and incidence of 300 interstitial pneumonia with DPP4 inhibitor (vildagliptin) (Japanese Adverse Drug Event Report 301 database, 2004; Sada et al., 2014; Tanaka et al., 2020) . Further, loss of DPP4 activity is associated 302 with a prothrombotic state in myocardial microvessels due to the upregulation of the procoagulant 303 tissue factor (Krijnen et al., 2012) , and reduced postoperative DPP4 activity has been associated 304

with worse patient outcomes after cardiac surgery due to paradoxical impairment of angiogenesis 305 and endothelial function (Sun et al., 2013; Noels et al., 2018) . immune response and infect host cells (Carnec et al., 2015; Vitallé et al., 2019) . Further, CD300 314 molecules downregulate the cytolytic activity of natural killer (NK) cells against infected cells 315 (Vitallé et al., 2019) . Duplication of the region involving CD300 genes in this patient may lead to 316 overexpression of these genes that help the virus to evade the immune response leading to disease 317 severity upon infection. 318

The 162.2 kb duplication partially duplicating the EDARADD gene is among the three 319 genes identified to cause ectodermal dysplasia (ED) and is involved in NF-kB activation 320 (Martínez-Romero et al., 2019; Smahi et al., 2002) . The two patients with this SV did not have 321 any form of ectodermal dysplasia and the SV was not found in any public database (DGV and 322 gnomAD, last accessed 11/8/2020). To our knowledge, nine EDARADD pathogenic sequencing 323 variants have been described, three leading to an autosomal recessive inheritance and six to an 324 autosomal dominant mode of inheritance (Cluzeau et al., 2019 the EDARADD gene that did not impact the interaction between EDAR and EDARADD proteins 333 but led to an impaired ability of the gene to activate NF-κB signaling (Wohlfart et al., 2016 ) . 334

Notably, this patient did not exhibit a phenotype consistent with autosomal dominant ED. Further 335 J o u r n a l P r e -p r o o f investigation of the functional consequences of these variants is needed for a more informed 336

interpretation. 337

While these findings are preliminary in the above-mentioned immune genes, some 338 candidate genes/loci suggest interesting follow-up opportunities. Generally, some observations 339 seem to be in line with individual variants affecting key immune response genes -collectively they 340 may well explain a few percent of all severe/life-threatening COVID-19 cases (Van der Made et  341 al., 2020; Zhang et al., 2020 ) . The highlighted rare/ unique SVs all deserve further follow-up 342 before any conclusions can be drawn. These may include segregation analyses in the respective 343 families; and additional downstream expression analysis or protein levels in patient plasma as well 344

as functional studies. It would also be of interest to learn whether any of the identified candidate 345 genes harbor rare/unique point mutations (SNVs/InDels) in WES/WGS data of severe COVID-19 346 cases or show altered expression levels in larger cohorts of severe COVID-19 cases. 347

Two rare/unique SVs impacting the keratin genes (KRT15 and KRT19), and ZNF443 genes were 349 found in three patients. A rare/unique SV, with a ~ 28.4 kb duplication including two genes 350 (KRT15 and KRT19) was identified in one patient (case 2). Keratins are intermediate filament 351

proteins responsible for the structural integrity of epithelial cells and are part of the cytoskeletal 352 structure of host cells. The keratins, including KRT15, have been identified to play a major role in 353 the cell-to-cell transmission (i.e. spread) of influenza and SARS-CoV-2 viruses, and are 354 upregulated in the respiratory tract during infection (Pociask et al., 2017; Basu et al., 2020) . 355

Another rare/unique duplication was found in the ZNF443 gene, which has sequence homology to 356 the SARS-CoV-2 virus and might aid in the replication process (Pasquier et al., 2020; Pasquier et 357 al., 2020) . Duplication of these genes could lead to overexpression and it is hypothesized that this 358 might assist viral replication and spread leading to increased disease severity. 359

The current study provides a powerful framework for investigating structural variations in 360 host genomes that might predispose individuals to severe COVID-19. To our knowledge, this is 361 the first study investigating structural variation using optical genome mapping in host-virus 362 interactions in SARS-CoV-2 infected patients. The diverse inter-individual variability observed in 363 the human population after SARS-CoV-2 infection attributed to the disease severity, 364

transmissibility, viral titers, and immune response highlights that numerous pathways/ genes are 365 involved in this complex host-viral interaction. It is insufficient to consider only genomic variation 366 at the level of SNVs/ small indels to understand host variability in response to COVID-19 367 exposure. The present investigation highlights rare SVs in genes implicated in distinct pathways 368 of host-viral interaction disrupted by structural variations in patients with severe COVID-19. The 369 events affecting these genes might have predisposed these patients towards a severe disease course. 370

Further, several findings in this study are consistent with and support previous reports implicating 371 the type I interferon pathway and type I interferon response in the pathogenesis of One finding, a rare SV leading to partial duplication of the TLR negative regulator, STK26, and 373 the coincident upregulation of STK26 is especially intriguing. Remarkably, this finding led us to 374 discover that, relative to levels in asymptomatic COVID-19 cases, STK26 was upregulated in all 375 13 tested patients with severe COVID-19, with the highest expression in the patient with the partial 376 duplication. This overexpression may be part of a more widespread severe response profile, but 377 direct involvement of the SV identified in the respective individual in disease severity seems 378 possible. Another rare SV leads to a partial deletion of DPP4, associated with very low sDPP4 379 levels in the respective individual. Intriguingly, we identified low sDPP4 levels in all severely 380 affected COVID-19 patients in line with previous literature. In summary, we propose that genomic 381 analyses to understand the human variation that impacts the predisposition to severe COVID-19 382

should include systematic SV assessment to fully understand the host genome. Here we exemplify 383 that rare SVs may influence the host immune response, and highlight two rare SVs in two severely 384 affected individuals that may add to a better understanding of COVID-19 host genetics. 385

There are some limitations in the present investigation, which will benefit from additional 387

follow-up studies. Although the study is limited to a small patient population, rare SVs were 388 significantly enriched for immune genes, so the findings would be made stronger by validation in 389 a larger cohort. Second, the study focused on large SVs (>500 bp) and did not investigate smaller 390 indels that might also be implicated as predisposition factors associated with severe COVID-19. 391

Third, better-matched controls for the genomic analysis, such as infected close relatives with 392 distinct clinical manifestations (mild/ asymptomatic), would help control for the confounding 393

influences of common environmental factors. Gaining access to more ideal control samples and 394 performing optical mapping in larger cohorts was beyond the scope of this initial study. However, 395

to address these limitations, the following measures were implemented: comparing the frequency 396 of SVs to Bionano control dataset and public databases (DGV and gnomAD), and identifying 397 unique SVs that do not appear in controls and SVs that overlap/ disrupt the coding region of the 398 genes implicated in host-viral interaction. Fourth, the samples of the patients were not drawn 399 during the same point in their disease course; however, the functional data shows a clear distinction 400

between asymptomatic patients and those with severe disease. Nevertheless, the whole genome 401 investigation of 52 severely ill patients with COVID-19 identified candidate loci that may provide 402 novel insights into the pathogenesis of severe COVID-19 in some cases. 403

The authors thank Christoph Lange for providing valuable feedback for the manuscript and Ben 405

Clifford for providing technical support. Genomics, and BMS. AHB has received funding from the NIH, MDA (USA), AFM Telethon, 418

Alexion Pharmaceuticals Inc., Audentes Therapeutics Inc., Dynacure SAS, and Pfizer Inc. He has 419 consulted and received compensation or honoraria from Asklepios BioPharmaceutical Inc, 420

Audentes Therapeutics, Biogen, F. Hoffman-La Roche AG, GLG Inc, Guidepoint Global, and 421

Kate Therapeutics, and holds equity in Ballard Biologics and Kate Therapeutics. 422 Figure 1 Workflow diagram for analysis of COVID-19 patient SVs. Figure 9a-h Expression and protein analysis of select markers. a. STK26 transcripts were found to be significantly (7.2 ± 2.3 vs. 1.1 ± 0.5; p<0.001) increased in severely ill patients compared to asymptomatic controls, with the highest expression observed in patient-44 (11.7 fold), who was the patient that harbored the SV partially duplicating the 5'UTR and coding exon 1 of the STK26 gene, b. The gene transcripts of STK26 were found to be significantly increased in males (4.8 ± 1.3 vs. 1.2 ± 0.6; p<0.001) and, c. females (9.0 ± 2.6 vs. 1.1 ± 0.4; p<0.001) in severely ill patients compared to asymptomatic controls, d. The gene transcripts for TRAF6 (29.7 ± 11.8 vs. 1.6 ± 1.8; p< 0.001) and e. IRF3 (2.8 ± 1.2 vs. 1.3 ± 0.9; p<0.001) were significantly increased, whereas, the gene transcripts of interferon-stimulated genes, f. ISG15 (0.9 ± 1.5 vs. 2.7 ± 4.1; p<0.05) and g. IFIT1 (0.5 ± 0.7 vs. 1.7 ± 2.0; p<0.001) was significantly decreased in severely ill patients compared to asymptomatic controls, h. The sDPP4 serum concentration was significantly decreased in severely ill patients compared to asymptomatic controls (1732.4 ± 1049.6 vs. 3015.3 ± 853.0; p<0.05) ng/ml, with the lowest concentration observed in patient 38 (117 ng/ml), who harbored the SV partially deleting exon 3-5 of the DPP4 gene. 

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Ravindra Kolhe (rkolhe@augusta.edu).

This study did not generate new unique reagents.

Additional supplemental items are available from Mendeley Data at http://dx.doi.org/10.17632/fmvxxbdtpz.1. DOI is also included in key-resource table.

Any additional information required to reanalyze the data reported in this work paper is available from the lead contact upon request.

During the period from March 2020 to February 2021, 52 severely ill patients were identified for this study. The criteria for inclusion included patients with a confirmed SARS-CoV-2 RT-PCR test (from nasopharyngeal swabs or other biological fluids), and a requirement for mechanical ventilation or a fraction of inspired oxygen (FiO2) of at least 60% or more. The samples were collected under an approved HAC by the IRB Committee A (IRB REGISTRATION # 1597188-2), Augusta University, GA. Based on the IRB approval, all PHI was removed, and all data was anonymized before accessing for the study.

Peripheral blood from critically ill COVID-19 patients was drawn and used to isolate ultra-high molecular weight (UHMW) DNA prepared for analysis on the Bionano Genomics Saphyr® platform (Bionano Genomics, San Diego, USA, #90001) following the manufacturer's protocols (Bionano Genomics, San Diego, USA, #90057)). Briefly, a frozen blood aliquot (650μl) was thawed and cells were counted using HemoCue (Microcuvettes and WBC analyzer, HemoCue Holding AB, Ängelholm, Sweden). Subsequently, a blood aliquot comprising approximately 1.5 million nucleated white blood cells was centrifuged and digested with Proteinase K. DNA was precipitated using isopropanol and washed using buffers (buffer A and B), while the DNA remained adhered to the nanobind magnetic disk. The UHMW bound DNA was resuspended in elution buffer and quantified with Qubit dsDNA BR assay kits (ThermoFisher Scientific, San Francisco, USA, #Q32850) using Qubit fluorimeter (ThermoFisher Scientific, San Francisco, USA, #Q33226).

DNA labeling was performed following manufacturer's protocols (Bionano Genomics, USA, #80005) in which Direct Labeling Enzyme 1 (DLE-1) reactions to a specific 6-base sequence motif (CTTAAG) in the genome were carried out using 750 ng of purified high molecular weight DNA. Labeled DNA was quantified using Qubit dsDNA HS assay kits (ThermoFisher Scientific, San Francisco, USA, #Q32851), and loaded onto flow cells of Saphyr chips (Bionano Genomics, USA, #20366) for optical imaging. The fluorescently labeled DNA molecules were imaged on the Saphyr platform after the labeled DNA molecules were electrophoretically linearized in the nanochannel arrays. Effective genome coverage of approximately 100X was achieved for tested samples after evaluating the molecule quality metrics. The quality control metrics for each sample achieved the recommended molecule map rates of greater than 70% and molecule N50 values greater than 250kb in size.

Genome analyses were performed using Bionano Access (v.1.5)/Bionano Solve (v.3.5) software, a de novo assembly analysis was performed on all the samples to assess and interrogate all germline SVs. Briefly, molecules of a given sample dataset were first de novo assembled into consensus genome maps, the genome maps were aligned to the GRCH37 reference human genome assembly. SVs were identified where de novo assemblies differed from the GRCH37 reference genome, insertion, duplications, deletions, inversions, and translocations could be called based on this alignment. SVs generated by the de novo assembly pipeline were then annotated with known canonical gene sets extracted from the reference genome assembly and compared to a control dataset to estimate the population frequency of SVs.

Rare/unique SVs (>500bp) were investigated to determine candidate gene/loci as potentially strong predisposing factors associated with severe COVID-19. Unbiased whole-genome analysis of SVs was performed to identify unique/rare genic SVs in these patients that did not appear in the population dataset (Bionano controls comprising 267 individuals). Additionally, only SVs disrupting the coding region(s) of the gene(s) were selected and reviewed for relevance to response to COVID-19 infection. The Bionano control dataset includes 267 healthy individuals, of which 45 were African, 16 were Admixed American, 17 were East Asian, 44 were European, 15 were South Asian and 180 were of unknown origin (Levy-Sakin et al., 2019; Izzy et al., 2020; Ebert et al., 2021) . The frequency of the SVs were also determined using the public database (gnomAD). (Figure 1 ).

Quantitative PCR (qPCR) was used to confirm the selected SVs (copy number gains and losses). Relative quantitation of genomic dosage was determined using the QuantStudio 3 real-time cycler (Thermo Fisher Scientific, San Francisco, USA, # A28136) and calculated by the relative threshold cycle (ddCt) method (Livak et al., 2001) . PCR amplicons were generated in triplicate for each individual and four controls. Genomic dosage for the selected SVs (EDARADD, DPP4, ZDHHC1, KRT15, CD300A, ZNF443, STK26,) were determined by SYBR green incorporation using RNAseP as the reference (BioRad, USA). Three primer pairs were designed for each SV using the Primer 3.0 software (List of primer sequences and targets is available in Supplementary file 1). Relative genomic dosage was calculated as 2 -ΔΔCT where ΔCT=(mean CtTarget)-(mean CtReference) and ΔΔCT= ΔCTpatient-ΔCTcontrol.

To provide an independent assessment of the SVs called by the Bionano Solve pipelines developed by Bionano Genomics, we used a novel method, FaNDOM (Fast Nested Distance-based seeding of Optical Maps) (https://github.com/jluebeck/FaNDOM) (Dehkordi et al., 2021) . FaNDOM maps optical map fragments to an in silico digested reference genome, relying on a fast filtering strategy to provide an order of magnitude speedup while still maintaining high sensitivity over 95% for concordant reads, and 79% for SVs on the benchmark NA12878 human genome. FaNDOM was used on the COVID-19 patient data to call breakpoints (two distinct reference positions that are adjacent in the donor), multi-chromosomal translocation, and insertion events. SVs were called on breakpoints based on the orientation of the fragments mapping to the breakpoint, with a (+,+) orientation suggestive of a deletion, (-,-) orientation suggestive of a tandem duplication, and opposing orientation suggesting an inversion or translocation. The SVs called by FaNDOM were used to independently confirm SVs called by Bionano Access Software.

Total RNA was isolated from the peripheral blood of 15 asymptomatic patients [7 male, 8 female, age range 25-59 years [mean 40.8 ± 11.5 (SD)] and 13 severely ill COVID-19 patients [6 male and 7 female, age range 19-81 years [mean 60.9 ± 15.1 (SD)], using mRNeasy mini kit (QIAGEN, Germany). Peripheral blood was collected from the asymptomatic controls during active infection (positive for SARS-CoV-2 by RT-PCR at time of blood collection), and during ICU treatment for the severely ill patients. The quantity of total RNA from the samples was determined by an ultraviolet spectrophotometer (Nanodrop, Thermo Fisher Scientific, and Pittsburgh, PA). Total RNA (500 ng) was reverse transcribed using the iScript cDNA synthesis kit (170-8891) from BioRad Laboratories (Hercules, CA). Quantitative real-time PCR (q-RT-PCR) was performed using gene-specific primers, and an SYBR Green assay on the QuantStudio 3 system (Thermo Fisher Scientific, CA) (Supplementary file 1) . The specific products were confirmed by SYBR green single melt curve analysis. The results were normalized to the expression of the 18S rRNA housekeeping gene and the relative fold change was calculated using the delta-delta Ct method.

sDPP4 serum concentrations were measured in 8 asymptomatic and severely ill patients (4 male, 4 female) in each group, respectively, using the Enzyme-linked immunosorbent assay (ELISA) (ThermoFisher Scientific, USA, Cat# EHDPP4) following the manufacturer's instructions.

Statistical analyses was performed for qPCR expression and sDPP4 serum concentration experiments. Comparison between groups were made using unpaired T-test and a p value <0.05 was considered statistically significant. 

Severe Covid-19

China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Factors associated with COVID-19-related death using OpenSAFELY

Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

Younger Adults Caught in COVID-19 Crosshairs as Demographics Shift

The Role of Host Genetic Factors in Coronavirus Susceptibility: Review of Animal and Systematic Review of Human Literature

Association between ABO blood group system and COVID-19 susceptibility in Wuhan

Relationship between the ABO Blood Group and the COVID-19

Genomewide Association Study of Severe Covid-19 with Respiratory Failure

Genetic mechanisms of critical illness in Covid-19

Presence of Genetic Variants Among Young Men With Severe COVID-19

Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Pan-ancestry exome-wide association analyses of COVID-19 outcomes in 586,157 individuals

The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic

Genetic variation, comparative genomics, and the diagnosis of disease

Genome maps across 26 human populations reveal population-specific patterns of structural variation

Genetic Variation, Comparative Genomics, and the Diagnosis of Disease

Structural variant calling: the long and the short of it

Complete haplotype sequence of the human immunoglobulin heavy-chain variable, diversity, and joining genes and characterization of allelic and copy-number variation

Population-specific profiling of CCL3L1 copy number of the three major ethnic groups in Malaysia and the implication on HIV susceptibility

Human copy number variants are enriched in regions of low mappability

Mapping bias overestimates reference allele frequencies at the HLA genes in the 1000 genomes project phase I data

Multi-platform discovery of haplotype-resolved structural variation in human genomes

Optical genome mapping enables constitutional chromosomal aberration detection

Next-generation cytogenetics: Comprehensive assessment of 52 hematological malignancy genomes by optical genome mapping

Characteristics and Outcomes of Latinx Patients With COVID-19 in Comparison With Other Ethnic and Racial Groups

Haplotyperesolved diverse human genomes and integrated analysis of structural variation

Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method

Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 -Georgia

The kinase MST4 limits inflammatory responses through direct phosphorylation of the adaptor TRAF6

Dipeptidyl peptidase-4 at the interface between inflammation and metabolism

Innate immune pattern recognition: a cell biological perspective

Pathogen recognition and innate immunity

IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes

In silico analyses on the comparative sensing of SARS-CoV-2 mRNA by intracellular TLRs of human

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Dual UTR-A novel 5′ untranslated region design for synthetic biology applications

TRAF6 establishes innate immune responses by activating NF-κB and IRF7 upon sensing cytosolic viral RNA and DNA

COVID-19 patients upregulate toll-like receptor 4-mediated inflammatory signaling that mimics bacterial sepsis

Post-Mendelian genetic model in COVID-19. medRxiv

Endoplasmic reticulum transmembrane proteins ZDHHC1 and STING both act as direct adaptors for IRF3 activation in teleost

p53 promotes ZDHHC1-mediated IFITM3 palmitoylation to inhibit Japanese encephalitis virus replication

The frequency of combined IFITM3 haplotype involving the reference alleles of both rs12252 and rs34481144 is in line with COVID-19 standardized mortality ratio of ethnic groups in England

DPP4-directed therapeutic strategies for MERS-CoV

Reduction of soluble dipeptidyl peptidase 4 levels in plasma of patients infected with Middle East respiratory syndrome coronavirus

Circulating levels of soluble Dipeptidylpeptidase-4 are reduced in human subjects hospitalized for severe COVID-19 infections

Furniss J. Genetic mechanisms of critical illness in Covid-19

The MERS-CoV receptor DPP4 as a candidate binding target of the SARS-CoV-2 spike

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system

Sarcoid-like lung granulomas in a hemodialysis patient treated with a dipeptidyl peptidase-4 inhibitor

Vildagliptin-induced ground-glass nodules mimicking lung metastases in a cancer patient receiving Lactobacillus probiotic supplementation

Paradoxical impairment of angiogenesis, endothelial function and circulating number of endothelial progenitor cells in DPP4-deficient rat after critical limb ischemia

Reduced post-operative DPP4 activity associated with worse patient outcome after cardiac surgery

The Phosphatidylserine and Phosphatidylethanolamine Receptor CD300a Binds Dengue Virus and Enhances Infection

CD300 receptor family in viral infections

EDA, EDAR, EDARADD and WNT10A allelic variants in patients with ectodermal derivative impairment in the Spanish population

The NF-kappaB signalling pathway in human diseases: from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes

First homozygous large deletion in EDARADD gene associated with a severe form of anhidrotic ectodermal dysplasia

Autosomal dominant anhidrotic ectodermal dysplasias at the EDARADD locus

A novel missense mutation in the gene EDARADD associated with an unusual phenotype of hypohidrotic ectodermal dysplasia

Epigenetic and transcriptomic regulation of lung repair during recovery from influenza infection

Study of cell to cell transmission of SARS CoV 2 virus particle using gene network from micro array data

Computational search of hybrid human/SARS-CoV-2 dsRNA reveals unique viral sequences that diverge from other coronavirus strains

Supplementary file 5: Comparison of traditional cytogenetic technologies, short-read sequencing, long-read sequencing and optical genome mapping.